Improvements in Neurocognitive Function and Mood Following Adjunctive Treatment with Mifepristone (RU-486) in Bipolar Disorder
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
High cortisol levels are found in severe mood disorders, particularly bipolar disorder. Hypercortisolaemia may cause or exacerbate both neurocognitive impairment and depressive symptoms. We hypothesized that antiglucocorticoid treatments, particularly corticosteroid receptor antagonists, would improve neurocognitive functioning and attenuate depressive symptoms in this disorder. To test this hypothesis, 20 bipolar patients were treated with 600 mg/day of the corticosteroid receptor antagonist mifepristone (RU-486) or placebo for 1 week in a double-blind crossover design. Over the total 6 weeks of the study, neurocognitive and neuroendocrine function were evaluated at baseline, days 21 and 42. Mood symptoms were evaluated weekly. Nineteen subjects completed the protocol; there were no drop-outs due to adverse events. Following treatment with mifepristone, selective improvement in neurocognitive functioning was observed. Spatial working memory performance was significantly improved compared to placebo (19.8% improvement over placebo). Measures of verbal fluency and spatial recognition memory were also improved after mifepristone. Beneficial effects on mood were found; Hamilton Depression Rating Scale scores were significantly reduced compared to baseline (mean reduction of 5.1 points) as were Montgomery-Asberg Depression Rating Scale scores (mean reduction of 6.05 points). No significant change occurred after placebo. These data require replication but provide preliminary evidence that glucocorticoid receptor antagonists may have useful cognitive-enhancing and possibly antidepressant properties in bipolar disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“drugs targeting the HPA axis can improve BD symptoms (Young et al. 2004;Young ,2014;Juruena et al. 2009).”
From The HPA axis in bipolar disorder: Systematic review and meta-analysis (2016) · cites this paper as Young et al. 2004
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 3×
“…symptomatic improvement, the antidepressant effect of mifepristone was the principal focus, therefore the outcome measures of interest were the 17-item Hamilton Depression Rating Scale (HDRS17; Hamilton, 1960) and the Montgomery–Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979).”
MethodInfluentialA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 3×
“…symptomatic improvement, the antidepressant effect of mifepristone was the principal focus, therefore the outcome measures of interest were the 17-item Hamilton Depression Rating Scale (HDRS17; Hamilton, 1960) and the Montgomery–Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979).”
MethodInfluentialKessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370 · cited 1×
“Bipolar disorder is a chronic and recurrent illness, with a lifetime incidence of at least 1% (Kessler et al, 1994).”
BackgroundThe Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 1×
“Other secondary scales consisted of the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962) and the Young Mania Rating Scale (YMRS; Young et al, 1978).”
MethodA Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 1×
“Other secondary scales consisted of the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962) and the Young Mania Rating Scale (YMRS; Young et al, 1978).”
MethodNeuropsychological assessment.
Cipolotti, L., & Warrington, E. K. (1995) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.58.6.655 · Cited by 3,234
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106 · cited 1×
“Although the illness is defined by the occurrence of mania, the depressed phase predominates (Judd et al, 2002, 2003) and represents the greatest therapeutic challenge.”
BackgroundGlucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016 · cited 2×
“It has been suggested that abnormalities in hypothalamic–pituitary– adrenal (HPA) axis function may cause or exacerbate both neurocognitive impairment and depressive symptoms (McQuade and Young, 2000; Sapolsky, 2000).”
BackgroundSmithson, M. (2000) · SAGE Publications Ltd eBooks · doi:10.4135/9781446218525 · Cited by 1,871
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243 · cited 1×
“Although the illness is defined by the occurrence of mania, the depressed phase predominates (Judd et al, 2002, 2003) and represents the greatest therapeutic challenge.”
Background
Research works printed but not linked: 5
- Cegalis J, Bowlin J (1991). Vigil: Software for the Assessment of Attention. Forthought: Nashua, NH.
- First MB, Spitzer RL, Williams JBW, Gibbon M (1995). Structured Clinical Interview for DSM-IV (SCID-I), Research Version. Biometrics Research Department, New York State Psychiatric Institute: New York.
- Høyberg ØJ, Wik G, Mehtonen OP, Peeters BWMM, Sennef C (2002). ORG 34517, a selective glucocorticoid receptor antagonist with potent antidepressant activity: first clinical results. Int J Neuropsychopharmacol 5: S148.
- Lopez JF, Little KY, Lopez-Figueroa AL, Lopez-Figueroa MO, Watson SJ (2003). Glucocorticoid and mineralocorticoid receptor mRNA levels in the hippocampus and prefrontal cortex of subjects with mood disorders and schizophrenia. Biol Psychiatry 53: 489.
- Thompson JM, Gray JM, Hughes J, Watson S, Ferrier I, Young AH (2000). A component process analysis of working memory dysfunction in bipolar affective disorder. J Psychopharmacol (Oxf) 14: A24.
Cited by
Items 201–300 of 315
Mukherjee, D., Weissenkampen, J. D., Wasserman, E. J., Krishnamurthy, V., Millett, C. E., Conway, S., & Saunders, E. F. H. (2021) · Neuropsychobiology · doi:10.1159/000517343 · Cited by 19
Matsumoto, Y., Niwa, M., Mouri, A., Noda, Y., Fukushima, T., Ozaki, N., & Nabeshima, T. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4704-8 · Cited by 15
Chen, W., Liu, H., Cheng, Y., Li, H., Huang, C., Ding, Y., Huang, M., Chiu, C., Tu, Y., & Kuo, P. (2021) · Clinical Epidemiology · doi:10.2147/clep.s335584 · Cited by 14
Rakotomamonjy, J., Lévénès, C., Baulieu, E. E., Schumacher, M., & Ghoumari, A. M. (2011) · The FASEB Journal · doi:10.1096/fj.11-183384 · Cited by 14
“It also selectively improves neurocognitive function and has antidepressant properties in patients with bipolar disorders (8).”
BackgroundCurrent Treatment Options for Cognitive Impairment in Bipolar Disorder: a Review
Douglas, K. M., & Rheenen, T. E. V. (2016) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-016-0092-7 · Cited by 14
“Pharmacological intervention studies The pharmacological intervention studies investigated a wide variety of pharmacological agents including hormones controlling erythropoiesis (erythropoietin [51]) and glucose levels (insulin [47]), a dopamine agonist (pramipexole [45, 50]), an antioxidant supplement (N-acetylcystei…”
BackgroundMethodInfluentialGenes involved in glucocorticoid receptor signalling affect susceptibility to mood disorders
Szczepankiewicz, D., Narożna, B., Celichowski, P., Sakrajda, K., Kolodziejski, P. A., Banach, E., Zakowicz, P. T., Pruszyńska‐Oszmałek, E., Pawlak, J., Wiłkość-Dębczyńska, M., et al. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1766109 · Cited by 15
“Moreover, GR non-selective antagonist mifepristone (RU486) was effective in inducing a rapid improvement of depressive symptoms in both preclinical and clinical studies (Young et al. 2004; Oomen et al. 2007; Blasey et al. 2009; Wulsin et al. 2010).”
BackgroundAfşar, B. (2014) · Psychiatric Quarterly · doi:10.1007/s11126-014-9307-5 · Cited by 18
“Lastly, it was shown that some glucorticoid antagonist showed anti-depressant effects [20, 21].”
BackgroundDonoghue, K., Rose, A. K., Coulton, S., Coleman, R., Milward, J., Phillips, T., Drummond, C., & Little, H. J. (2020) · Trials · doi:10.1186/s13063-020-04726-z · Cited by 14
O'Brien, J. T. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000205769.43171.c0 · Cited by 13
Tournikioti, K., Alevizaki, M., Michopoulos, I., Mantzou, A., Soldatos, C. R., Douzenis, A., Dikeos, D. G., & Ferentinos, P. P. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114301 · Cited by 13
Drugs under early investigation for the treatment of bipolar disorder
Konstantakopoulos, G., Dimitrakopoulos, S., & Michalopoulou, P. G. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1019061 · Cited by 12
“Ebselen IMPase inhibition Induces lithium-like effects on mouse behaviour of rearing and amphetamine-induced hyperactivity [63]”
BackgroundWatson, S., Horton, K., Bulmer, S., Carlile, J., Corcoran, C., Gallagher, P., & Ferrier, I. N. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1525-4 · Cited by 11
Self-citationCortisol to Dehydroepiandrosterone Sulphate Ratio and Executive Function in Bipolar Disorder
Tournikioti, K., Alevizaki, M. K., Michopoulos, I., Mantzou, A., Soldatos, C. R., Douzenis, A., Dikeos, D. G., & Ferentinos, P. P. (2021) · Neuropsychobiology · doi:10.1159/000513512 · Cited by 11
Gulyaeva, N. V. (2024) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093024040203 · Cited by 10
Cognitive effects of mifepristone in overweight, euthymic adults with depressive disorders
Roat-Shumway, S., Wroolie, T., Watson, K. T., Schatzberg, A. F., & Rasgon, N. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.014 · Cited by 10
New Pharmacological Interventions in Bipolar Disorder
Juruena, M. F., Jelen, L. A., Young, A. H., & Cleare, A. J. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_181 · Cited by 10
Self-citationMultiple Clinical Indications of Mifepristone: A Systematic Review
Mathew, S. A., Ticsa, M. S., Qadir, S., Rezene, A., & Khanna, D. (2023) · Cureus · doi:10.7759/cureus.48372 · Cited by 14
“While the exact cause of the weight gain is unknown, mifepristone was shown to significantly reduce weight gain in patients when taken alongside risperidone or olanzapine [21].”
BackgroundMethodInfluentialUban, K. A., Bodnar, T. S., Butts, K. A., Sliwowska, J. H., Comeau, W. L., & Weinberg, J. (2010) · Health care and disease management · doi:10.1002/9783527632510.ch5 · Cited by 11
Update on augmentation of antidepressant response in resistant depression
DeBattista, C., & Lembke, A. (2005) · Current Psychiatry Reports · doi:10.1007/s11920-005-0064-x · Cited by 9
Should bipolar disorder treatment be modified depending on staging?
Passos, I. C., & Kapczinski, F. P. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1268532 · Cited by 9
Garner, B., Pariante, C. M., Wood, S. J., Velakoulis, D., Phillips, L., Soulsby, B., Brewer, W. J., Smith, D. J., Dazzan, P., Berger, G. E., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.018 · Cited by 8
Emerging novel treatments for severe mood disorders involving cellular plasticity cascades
Machado‐Vieira, R., Zarate, C. A., & Manji, H. K. (2006) · Current Psychosis & Therapeutics Reports · doi:10.1007/bf02629394 · Cited by 8
Hormone circuit explains why most HPA drugs fail for mood disorders and predicts the few that work
Milo, T., Halber, S. N., Raz, M., Danan, D., Mayo, A., & Alon, U. S. (2025) · Molecular Systems Biology · doi:10.1038/s44320-024-00083-0 · Cited by 8
“The rise in cortisol agrees with observations from clinical trials using the GR antagonists (Table 1) (Murphy et al, 1993; Gallagher and Young, 2006; Young et al, 2004).”
Cognitive insight and introspective accuracy in individuals with bipolar disorder: A scoping review
Wels, L., Dalkner, N., Lenger, M., Fellendorf, F. T., Schönthaler, E. M. D., Harvey, P. D., & Reininghaus, E. Z. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.101132 · Cited by 9
“There is research examining the effects of pharmacological treatments on cognition in BD (e.g., Xu et al., 2020; Young et al., 2004), but no studies were found that speci fi cally examined the effects of medication on CI and IA in individuals with BD; this should certainly be considered in future…”
Vakalopoulos, C. (2010) · Mental Illness · doi:10.4081/mi.2010.e7 · Cited by 8
“The antiglucocorticoid mifepristone improves spatial working memory performance as well as mood in a group of bipolar patients.(11) Cortisol increases intracellular calcium and up-regulates the effects of both cholinergic and monoaminergic G-protein coupled signal transduction.”
BackgroundAffective Disorders: Depression and Bipolar Disorders
Blackburn, T. P., & Wasley, J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00163-2 · Cited by 8
The Treatment of Bipolar Depression: Current Status and Future Perspectives
Jelen, L. A., & Young, A. H. (2020) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-020-00200-x · Cited by 7
Self-citationWei, B., Shi, Y., Yu, X., Cai, Y., Zhao, Y., Song, Y., Zhao, Z., Huo, M., Li, L., Gao, Q., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04244-y · Cited by 9
“Mifepristone, a GR antagonist, ameliorates depressive phenotypes in humans and rodents [35–37].”
New Drugs for Bipolar Disorder
Sanches, M., & Soares, J. C. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0231-1 · Cited by 7
“Mifepristone (Mifeprex; Danco Laboratories, New York, NY), a glucocorticoid receptor antagonist, has been tested regarding its effect on the cognitive functions of BD patients over a 6-week period [63].”
BackgroundTsapekos, D., Kalfas, M., Schandorff, J. M., Bonnín, C. D. M., Bowie, C. R., Balanzá‐Martínez, V., Burdick, K. E., Carvalho, A. F., Dols, A., Douglas, K. M., et al. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.70038 · Cited by 7
“Other baseline biomarkers associated with post-intervention cognitive changes included inflammatory cytokine levels [51], cortisol awakening response [55], and olfactory capacity [49].”
Self-citationZou, T., Yang, M., Chen, Z., Xie, H., Huang, J., Qin, Y., Liu, F., Chen, H., Xu, X., Chen, J., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05831-y · Cited by 5
“Two randomized, double-blind studies using the PRGE antagonist mifepristone to treat patients with BD found improvement of cognitive functioning, particularly in the areas of working memory and verbal learning [60, 61].”
BackgroundAntiglucocorticoid treatments for mood disorders
Gallagher, P., Malik, N., Newham, J. J., Young, A. H., Ferrier, I. N., & Mackin, P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005168.pub3 · Cited by 5
Self-citationChapter 5.7 Adrenal steroids and episodic memory: relevance to mood disorders
Alhaj, H. A., & McAllister-Williams, H. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(08)00232-4 · Cited by 6
Mifepristone enhances the neural efficiency of human visuospatial memory encoding and recall
Yalın, N., Kempton, M. J., Mazibuko, N., Mehta, M. A., Young, A. H., & Stokes, P. R. A. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.105116 · Cited by 7
Self-citationWang, H., Kan, W., Feng, Y., Feng, L., Yang, Y., Chen, P., Xu, J.-J., Si, T., Zhang, L., Wang, G., et al. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i12.1191 · Cited by 5
Antiglucocorticoids in psychiatry
McIsaac, S. A., Westrin, Å., & Young, A. H. (2009) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.105.001834 · Cited by 6
Self-citationAntiglucocorticoid treatments in mood disorders: efficacy and safety
Mackin, P., Gallagher, P., Froom, K., Geddes, J. R., & Young, A. H. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005168 · Cited by 5
Self-citationRetractedPharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders
Venero, C. (2015) · Cognitive Enhancement · doi:10.1016/b978-0-12-417042-1.00010-3 · Cited by 4
Asoprisnil as a Novel Ligand Interacting with Stress-Associated Glucocorticoid Receptor
Ejiohuo, O., Bajia, D., Pawlak, J., & Szczepankiewicz, A. (2024) · Biomedicines · doi:10.3390/biomedicines12122745 · Cited by 5
Kesavan, M., Rathi, L., Sinha, N., Reddy, P. V., & Bhaskar, M. (2025) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_696_24 · Cited by 5
“2004 [56] Mifepristone 600 mg/day Double-blind crossover trial 1 w treatment 2 w washout n =”
Serotonin Transporters: Implications for Antidepressant Drug Development
White, K. J., Walline, C. C., & Barker, E. L. (2008) · Springer eBooks · doi:10.1007/978-0-387-76678-2_13 · Cited by 4
Modulation of HPA Axis Function for Treatment of Mood Disorders
Brothers, S. P., Wahlestedt, C., & Nemeroff, C. B. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00276 · Cited by 4
Neurobiological aetiology of mood disorders
Goodwin, G. M. (2012) · doi:10.1093/med/9780199696758.003.0088 · Cited by 4
Role of corticosteroids in the antidepressant response
Pierscionek, T. J., Adekunte, O., Watson, S., Ferrier, I. N., & Alabi, A. (2014) · ChronoPhysiology and Therapy · doi:10.2147/cpt.s67272 · Cited by 6
“It is noteworthy that the bipolar mifepristone studies demonstrated a significant effect on spatial working memory, with no appreciable benefit on depressive symptoms.(136,137) It could be argued that future HPA efficacy studies should focus on improving neuropsychological performance.”
Self-citationShould bipolar disorder be considered a systemic illness?
Grande, I., Kunz, M., Potter, W. A., Balanzá‐Martínez, V., Vieta, E., & Kapczinski, F. P. (2011) · Neuropsychiatry · doi:10.2217/npy.10.7 · Cited by 5
Glucocorticoid effects on oxidative stress and mitochondrial dysfunction
Tang, V. M. (2012) · cIRcle (University of British Columbia) · doi:10.14288/1.0072794 · Cited by 4
“Importantly, it has been demonstrated that the GR system may be a potential therapeutic target for novel BD treatments, as the GR antagonist RU486 was shown to alleviate mood and cognitive symptoms in patients (Young et al., 2004).”
BackgroundPharmacological treatment of bipolar depression
Young, A. H., & Nemeroff, C. B. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511776922.004 · Cited by 3
Self-citationThe Hypothalamic–Pituitary–Adrenal Axis in Bipolar Disorder
Bond, D. J., & Young, A. H. (2007) · Medical psychiatry · doi:10.3109/9781420021158.008 · Cited by 3
Self-citationRezaei, H., Woodham, R. D., Ghazi-Noori, A.-R., Ritter, P. S., Bramon, E., Bauer, M., Young, A. H., & Fu, C. H. Y. (2025) · International Journal of Bipolar Disorders · doi:10.1186/s40345-025-00376-9 · Cited by 3
“…some cognitive benefits, particularly in improving working and visual memory, although the long-term effects are less clear, and mifepristone, a glucocorticoid receptor antagonist, has shown positive effects on spatial working memory and verbal fluency (Watson et al. 2012; Young et al. 2004).”
Self-citationModulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics
Yates, C. G., Kruse, J. L., Price, J. B., Robertson, A. A. B., & Tye, S. J. (2021) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-021-00249-9 · Cited by 4
Neuropsychological investigation in mood disorders
Keedwell, P. A., Surguladze, S. A., & Philips, M. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511642197.029 · Cited by 4
Quiroz, J. A., Chen, G., Drevets, W. C., Henter, I. D., & Manji, H. K. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.004 · Cited by 5
Cerebrovascular Disease and Bipolar Disorder
Byars, J. A., & Fiedorowicz, J. G. (2013) · Neuropsychiatric symptoms of neurological disease · doi:10.1007/978-1-4471-2428-3_14 · Cited by 3
“Some preliminary data indicates that the glucocorticoid receptor antagonist mifepristone may improve depressive and cognitive symptoms in BD, in line with the hypothesis of hypercortisolemia as an etiologic factor for BD [ 137 ].”
ResultNeurocognition in Bipolar Disorder
Torres, I. J., & Malhi, G. S. (2010) · Wiley eBooks · doi:10.1002/9780470661277.ch8 · Cited by 6
Genetic Transmission of Behavior and Its Neuroendocrine Correlates
Hambsch, B., Landgraf, R., Czibere, L., & Touma, C. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00084-x · Cited by 6
Targeting the HPA axis in major depression: does it work?
Claes, S. J. (2009) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.108.005983 · Cited by 4
HPA axis and cognitive dysfunction in mood disorders
Strawbridge, R., & Young, A. H. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139860567.014 · Cited by 3
Self-citationThe hypothalamic-Pituitary-Adrenal Axis: A Target for Intervention in Early Psychosis?
Porter, R. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2006.01898.x · Cited by 3
“RU486 is a potent GR antagonist which has been trialled with some effect in psychotic depression [31,32] while a recent preliminary study suggests a beneficial effect on cognitive function in bipolar depression [33].”
BackgroundCognitive Functioning in Bipolar Disorder
Martínez‐Arán, A., Jiménez, E., Montejo, L., Solé, B., Torrent, C., & Sánchez‐Moreno, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-85519-1_18 · Cited by 3
Insights, challenges and new frontiers for cognitive function in bipolar disorder
Miskowiak, K. W., Kjærstad, H. L., Vieta, E., & Yatham, L. N. (2026) · Nature Mental Health · doi:10.1038/s44220-026-00615-7 · Cited by 4
Gulyaeva, N. V. (2024) · Российский физиологический журнал им И М Сеченова · doi:10.31857/s0869813924070045 · Cited by 3
Metyrapone is an effective adjuvant treatment for major depression
Young, A. H. (2005) · Evidence-Based Mental Health · doi:10.1136/ebmh.8.3.72 · Cited by 2
Self-citationHusain, S., Kuzminski, S. J., Shad, M. U., Gabrielson, B., Bret, M. E., Osuji, I. J., & Brown, E. S. (2011) · Stress and Health · doi:10.1002/smi.1308 · Cited by 2
Recent advances in the biological treatment of mood disorders
McDonald, G., & Hallahan, B. P. (2009) · Irish Journal of Psychological Medicine · doi:10.1017/s0790966700000331 · Cited by 2
Underlying biological substrates associated with cognitive dysfunction in major depressive disorder
(2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139860567.012 · Cited by 2
The hypothalamic-pituitary-adrenal axis in bipolar disorder
Trinetti, J., Sforzini, L., & Pariante, C. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819182-8.00024-7 · Cited by 2
The dex/CRH test and the DST in patients with bipolar disorder and major depressive disorder
Watson, S., Gallagher, P., Smith, M. S., Ferrier, I. N., & Young, A. H. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2006.10.007 · Cited by 2
Self-citationAcute effects of mifepristone on emotional processing related brain activity: A functional MRI study
Yalın, N., Kempton, M. J., Mazibuko, N., Mehta, M. A., Young, A. H., & Stokes, P. R. A. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.08.500 · Cited by 1
Self-citationWang, T., Tsai, Y.-C., Huang, C.-C. J., Tsai, T.-Y., & Chang, Y.-H. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120834 · Cited by 1
Smith, E. G., Burke, P. R., Grogan, J. E., Fratoni, S. E., Wogsland, C. S., & Rothschild, A. J. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543784.010 · Cited by 1
Drug Treatment in the Metabolic Syndrome
Karathanasis, S. K., & SCHIEBINGER, R. J. (2005) · Elsevier eBooks · doi:10.1016/b978-84-8174-892-5.50027-9 · Cited by 1
Novel Therapeutic Approaches for Treating Bipolar Disorder
Machado‐Vieira, R., Henter, I. D., Baumann, J., Latov, D. R., Wheeler‐Castillo, C., & Zarate, C. A. (2011) · Wiley eBooks · doi:10.1002/9780470975114.ch21 · Cited by 1
Chengappa, K. N. R., Gannon, J. M., Acharya, L., & Rai, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-59192-6_17 · Cited by 2
Mackin, P., & Young, A. H. (2012) · Elsevier eBooks · doi:10.1016/b978-0-7020-3397-1.00021-5 · Cited by 1
Self-citationPharmacological Treatment of Bipolar Depression
Young, A. H., & Nemeroff, C. B. (2010) · Wiley eBooks · doi:10.1002/9780470661277.ch23 · Cited by 1
Self-citation(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as03 · Cited by 1
Wagner, U., & Born, J. (2004) · Springer eBooks · doi:10.1007/978-3-662-08959-0_7 · Cited by 2
Antidepressants: will new mechanisms of action improve poor outcomes?
Palaniyappan, L. K., & McAllister-Williams, H. (2008) · British Journal of Hospital Medicine · doi:10.12968/hmed.2008.69.2.28353 · Cited by 1
Novel Therapeutic Strategies for Bipolar Disorder
Machado‐Vieira, R., Manji, H. K., & Zarate, C. A. (2010) · Wiley eBooks · doi:10.1002/9780470661277.ch30 · Cited by 1
Interactions of stress and motor system function
Jadavji, N. M. (2008) · Open ULeth Scholarship (OPUS) (University of Lethbridge)
Der Einfluss von Ziprasidon auf den Schlaf und die Kortisolexkretion
Neumann, A.-C. H. (2007) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-699
Butts, K. A., Vacca, G., Ahn, S., Weinberg, J., Phillips, A. G., & Young, A. H. (2010) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(10)70314-x
“[2] Guerrini, R.”
BackgroundSelf-citationCountering core and co-morbid symptoms of affective disorders: Complementary multi-target strategies
Millan, M. J. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.10.007
Fear Learning as a Component of a Depressive Phenotype in Rodents
Marks, W. N. (2014) · University Library - University of Saskatchewan (University of Saskatchewan) · Cited by 1
Bipolar Bozuklukta Bilişsel BelirƟ lerin Doğasi ve Önemi
Bora, E., & Vahip, S. (2008) · Cited by 3
Potential novel treatments for bipolar depression
Zarate, C. A., & Manji, H. K. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8567-5_12 · Cited by 1
Glucocorticoid modulation of the mesocortical dopamine system and aspects of executive function
Butts, K. A. (2013) · cIRcle (University of British Columbia) · doi:10.14288/1.0073693
“Pronounced neurocognitive dysfunction is commonly reported in patients with bipolar disorder (Young et al., 2004; Watson et al., 2006) and may be attributed to alterations in PFC functioning that occur as a result of interactions between stress and DA function (Schatzberg et al., 1985).”
BackgroundCabezuelo, B. S. (2015) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
The neuroendocrinology of stress in the pathophysiology of bipolar disorders
Young, A. H., & Colasanti, A. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107477278.009
Self-citationThe Hypothalamic–Pituitary–Adrenal Axis in Bipolar Disorder
Bond, D. J., & Young, A. H. (2007) · CRC Press eBooks · doi:10.3109/9781420021158-11 · Cited by 1
Self-citationEffects of early life stress: Opportunities for pharmacological intervention
Loi, M. (2016) · Utrecht University Repository (Utrecht University)
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg002
Antiglucocorticoid and related treatments for psychosis
Garner, B., Phillips, L., Bendall, S., Parslow, R., & Hetrick, S. E. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006995 · Cited by 1
Potential Novel Treatments in Bipolar Depression
Machado‐Vieira, R., Henter, I. D., Manji, H. K., & Zarate, C. A. (2016) · Milestones in drug therapy · doi:10.1007/978-3-319-31689-5_12
(2005) · CRC Press eBooks · doi:10.1201/b14455-4
Wagner, U., & Born, J. (2010) · Springer eBooks · doi:10.1007/978-3-540-72340-0_7 · Cited by 2
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as03
The abortion ban and mifepristone’s threatening rise
Ali, M., Alvares, J., & Muhammad, A. (2022) · International Journal of Scientific Reports · doi:10.18203/issn.2454-2156.intjscirep20222696
Hair cortisol as a biomarker for mood in bipolar disorder: a pilot studyPreprint
Maimon, L., Milo, T., Haran, D., Cohen, B., Danon, T., Bren, A., Mayo, A., Rappaport, G. C., & Alon, U. S. (2023) · Research Square · doi:10.21203/rs.3.rs-2484487/v1 · Cited by 1
Metadata
- Authors
- Young, A. H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B. M., & Nicol Ferrier, I.
- Affiliations
- Newcastle University (GB)
- Corresponding author
- Young, Allan H
- Venue
- Neuropsychopharmacology
- Published
- 2004-05-05
- Volume
- 29
- Issue
- 8
- Pages
- 1538-1545
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2041573038
- Cited by
- 318
- References
- 38
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 13 · 2023: 6 · 2022: 2 · 2021: 11 · 2020: 9 · 2019: 5 · 2018: 14 · 2017: 8 · 2016: 16 · 2015: 13 · 2014: 18 · 2013: 12 · 2012: 14
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Stanley Medical Research Institute
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- mifepristone, RU486, bipolar disorder, glucocorticoid receptor antagonist, hypercortisolism, neurocognitive function, spatial working memory, verbal fluency, spatial recognition memory, depressive symptoms, antidepressant effects, cognitive enhancement
- MeSH terms
- Adult, Affect, Attention, Bipolar Disorder, Cognition, Double-Blind Method, Female, Hormone Antagonists, Humans, Hydrocortisone, Learning, Male, Memory, Short-Term, Middle Aged, Psychiatric Status Rating Scales, Psychomotor Performance, Receptors, Glucocorticoid, Space Perception, Verbal Learning, Mifepristone, Treatment Outcome, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.